We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+12.72%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$379M
AUM Growth
-$80.8M
Cap. Flow
-$143M
Cap. Flow %
-37.87%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$1.7M

Top Sells

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$145M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.55B
$355M 93.6%
2,503,528
-1,000,000
-29% -$145M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$10.9M 2.87%
1,000,002
+137,600
+16% +$1.7M
NVAX icon
3
Novavax
NVAX
$1.35B
$7.51M 1.98%
67,373
– –
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$5.87M 1.55%
45,884
– –

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2020 Portfolio in Review

As of Q4 2020, Foresite Capital Management II held 4 positions worth $379M, down 18% from $460M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $143M in Q4 2020, reducing 1 holding. Its largest reduction was 10x Genomics, cutting an estimated $145M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management II added an estimated $1.7M to Epizyme, Inc.

  • Foresite Capital Management II added most to Epizyme, Inc in Q4 2020, an estimated $1.7M increase.
  • Foresite Capital Management II's biggest Q4 2020 reduction was 10x Genomics, cutting an estimated $145M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $379M portfolio in Q4 2020.
  • Foresite Capital Management II opened 0 new positions and closed 0 in Q4 2020.
  • Foresite Capital Management II's portfolio value fell 18% quarter-over-quarter to $379M.

Based on Foresite Capital Management II's 13F filing for Q4 2020, filed 16 Feb 2021.